Literature DB >> 35936117

Outcomes of Hospitalized Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) With and Without a History of Peripheral Artery Disease.

Ayham Khrais1, Aaron Kahlam1, Anmol Mittal1, Sushil Ahlawat2.   

Abstract

Introduction Peripheral artery disease (PAD) is a common illness associated with an increased risk of complications and mortality. Gastroenterologists considering endoscopic retrograde cholangiopancreatography (ERCP) in these patients should weigh the benefits and risks carefully. Our goal is to analyze the hospital burden and complication rates in patients with PAD undergoing ERCP. Methods Using data from the National Inpatient Sample (NIS), patients over the age of 18 with and without PAD undergoing ERCP were identified utilizing the International Classification of Diseases (ICD)-9 codes. Primary outcomes included inpatient mortality, length of stay, and hospital charges. Secondary outcomes included rates of bile duct perforation, post-ERCP bleeding, acute pancreatitis, and cholangitis. Supplemental data, including household income and primary payer, were also analyzed. Independent t-tests were used for continuous data, chi-square tests for categorical data, and confounding variables (diabetes, age, gender, race) were controlled via multiple logistic regression. Results Most of the PAD group were male, while those in the non-PAD group were female (adjusted p<0.05). Mortality was higher in the PAD group (11.2% versus 8%; adjusted p<0.05). Members of the PAD group had longer lengths of stay (11.6 days versus 11 days; adjusted p<0.05) and more costly hospital stays ($108,006.49 versus $94,399.09; p<0.05). Members of the PAD group had higher rates of post-ERCP bleeding (5.2% versus 3.7%; adjusted p<0.05) and lower rates of cholangitis (6% versus 4%; adjusted p<0.05) and acute pancreatitis (6.9% versus 3.4%; adjusted p<0.05).  Conclusion Patients with PAD had an increased hospital burden but had a decreased risk of post-ERCP complications, including cholangitis and pancreatitis. Physicians performing risk stratification for patients with PAD undergoing ERCP must consider these specific complications and ensure that patients undergoing this procedure are fully aware of the dangers and benefits of ERCP prior to consenting to the procedure.
Copyright © 2022, Khrais et al.

Entities:  

Keywords:  advanced endoscopy; complications; ercp; peripheral artery disease; post-procedural bleeding

Year:  2022        PMID: 35936117      PMCID: PMC9352304          DOI: 10.7759/cureus.26585

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  30 in total

1.  Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease.

Authors:  K G Smolderen; K Wang; G de Pouvourville; B Brüggenjürgen; J Röther; U Zeymer; K G Parhofer; P G Steg; D L Bhatt; E A Magnuson
Journal:  Eur J Vasc Endovasc Surg       Date:  2011-10-15       Impact factor: 7.069

2.  Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters.

Authors:  Martin Sedlacek; John M Gemery; Ambrose L Cheung; Arnold S Bayer; Brian D Remillard
Journal:  Am J Kidney Dis       Date:  2007-03       Impact factor: 8.860

3.  A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis.

Authors:  B Joseph Elmunzer; James M Scheiman; Glen A Lehman; Amitabh Chak; Patrick Mosler; Peter D R Higgins; Rodney A Hayward; Joseph Romagnuolo; Grace H Elta; Stuart Sherman; Akbar K Waljee; Aparna Repaka; Matthew R Atkinson; Gregory A Cote; Richard S Kwon; Lee McHenry; Cyrus R Piraka; Erik J Wamsteker; James L Watkins; Sheryl J Korsnes; Suzette E Schmidt; Sarah M Turner; Sylvia Nicholson; Evan L Fogel
Journal:  N Engl J Med       Date:  2012-04-12       Impact factor: 91.245

4.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

5.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

6.  Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms.

Authors:  Mary McGrae McDermott; Kiang Liu; Philip Greenland; Jack M Guralnik; Michael H Criqui; Cheeling Chan; William H Pearce; Joseph R Schneider; Luigi Ferrucci; Lillian Celic; Lloyd M Taylor; Ed Vonesh; Gary J Martin; Elizabeth Clark
Journal:  JAMA       Date:  2004-07-28       Impact factor: 56.272

7.  Rivaroxaban in Peripheral Artery Disease after Revascularization.

Authors:  Marc P Bonaca; Rupert M Bauersachs; Sonia S Anand; E Sebastian Debus; Mark R Nehler; Manesh R Patel; Fabrizio Fanelli; Warren H Capell; Lihong Diao; Nicole Jaeger; Connie N Hess; Akos F Pap; John M Kittelson; Ivan Gudz; Lajos Mátyás; Dainis K Krievins; Rafael Diaz; Marianne Brodmann; Eva Muehlhofer; Lloyd P Haskell; Scott D Berkowitz; William R Hiatt
Journal:  N Engl J Med       Date:  2020-03-28       Impact factor: 91.245

8.  Efficacy and Safety of Propofol-Mediated Sedation for Outpatient Endoscopic Retrograde Cholangiopancreatography (ERCP).

Authors:  Juliana F Yang; Priya Farooq; Kate Zwilling; Devi Patel; Ali A Siddiqui
Journal:  Dig Dis Sci       Date:  2016-01-29       Impact factor: 3.199

Review 9.  What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials.

Authors:  Yunxiao Lyu; Yunxiao Cheng; Bin Wang; Yueming Xu; Weibing Du
Journal:  BMC Gastroenterol       Date:  2018-07-04       Impact factor: 3.067

10.  Prevalence of visceral artery involvement in patients with peripheral artery disease found on run-off MRA.

Authors:  Felix Streckenbach; Felix G Meinel; Felix Ammermann; Anke Busse; Andreas Neumann; Thomas Heller; Marc-André Weber; Ebba Beller
Journal:  BMC Med Imaging       Date:  2021-06-02       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.